{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T12:55:53Z","timestamp":1789563353728,"version":"build-2803163510"},"reference-count":65,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T00:00:00Z","timestamp":1759104000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001773","name":"University of New South Wales","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001773","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","award":["GNT2014079"],"award-info":[{"award-number":["GNT2014079"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","award":["GNT1163903"],"award-info":[{"award-number":["GNT1163903"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Metabolism"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.molmet.2025.102264","type":"journal-article","created":{"date-parts":[[2025,10,4]],"date-time":"2025-10-04T06:10:54Z","timestamp":1759558254000},"page":"102264","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Isotype-selective roles of hepatic acetyl-CoA carboxylases in a mouse model of fatty liver disease"],"prefix":"10.1016","volume":"102","author":[{"given":"Martina","family":"Beretta","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Calum S.","family":"Vancuylenburg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Riya","family":"Shrestha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ellen M.","family":"Olzomer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brenna","family":"Osborne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingyan","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suri","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam","family":"Hargreaves","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frances L.","family":"Byrne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyle L.","family":"Hoehn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.molmet.2025.102264_bib1","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2024.54707","article-title":"Estimated burden of metabolic dysfunction-associated steatotic liver disease in US adults, 2020 to 2050","volume":"8","author":"Le","year":"2025","journal-title":"JAMA Netw Open"},{"issue":"4","key":"10.1016\/j.molmet.2025.102264_bib2","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1097\/HEP.0000000000000004","article-title":"The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review","volume":"77","author":"Younossi","year":"2023","journal-title":"Hepatology"},{"issue":"6","key":"10.1016\/j.molmet.2025.102264_bib3","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1007\/s12519-024-00814-1","article-title":"Prevalence of nonalcoholic fatty liver disease in pediatrics and adolescents: a systematic review and meta-analysis","volume":"20","author":"Lee","year":"2024","journal-title":"World J Pediatr"},{"issue":"21","key":"10.1016\/j.molmet.2025.102264_bib4","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.1056\/NEJMra1503519","article-title":"Cause, pathogenesis, and treatment of nonalcoholic steatohepatitis","volume":"377","author":"Diehl","year":"2017","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.molmet.2025.102264_bib5","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1002\/hep.29085","article-title":"Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: systematic review and meta-analysis","volume":"65","author":"Dulai","year":"2017","journal-title":"Hepatology"},{"issue":"6","key":"10.1016\/j.molmet.2025.102264_bib6","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1016\/j.jhep.2017.07.027","article-title":"Fibrosis stage but not NASH predicts mortality and time to development of severe liver disease in biopsy-proven NAFLD","volume":"67","author":"Hagstrom","year":"2017","journal-title":"J Hepatol"},{"issue":"17","key":"10.1016\/j.molmet.2025.102264_bib7","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1056\/NEJMoa2029349","article-title":"Prospective study of outcomes in adults with nonalcoholic fatty liver disease","volume":"385","author":"Sanyal","year":"2021","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.molmet.2025.102264_bib8","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1053\/j.gastro.2015.04.005","article-title":"Weight loss through lifestyle modification significantly reduces features of nonalcoholic steatohepatitis","volume":"149","author":"Vilar-Gomez","year":"2015","journal-title":"Gastroenterology"},{"issue":"1","key":"10.1016\/j.molmet.2025.102264_bib9","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1002\/hep.23276","article-title":"Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis","volume":"51","author":"Promrat","year":"2010","journal-title":"Hepatology"},{"issue":"7","key":"10.1016\/j.molmet.2025.102264_bib10","doi-asserted-by":"crossref","DOI":"10.1016\/j.clinre.2024.102377","article-title":"Resmetirom's approval: highlighting the need for comprehensive approaches in NASH therapeutics","volume":"48","author":"Alshehade","year":"2024","journal-title":"Clin Res Hepatol Gastroenterol"},{"issue":"6","key":"10.1016\/j.molmet.2025.102264_bib11","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1056\/NEJMoa2309000","article-title":"A phase 3, randomized, controlled trial of resmetirom in NASH with liver fibrosis","volume":"390","author":"Harrison","year":"2024","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.molmet.2025.102264_bib12","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1053\/j.gastro.2013.11.049","article-title":"Increased de novo lipogenesis is a distinct characteristic of individuals with nonalcoholic fatty liver disease","volume":"146","author":"Lambert","year":"2014","journal-title":"Gastroenterology"},{"issue":"3","key":"10.1016\/j.molmet.2025.102264_bib13","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1172\/JCI134165","article-title":"Insulin resistance drives hepatic de novo lipogenesis in nonalcoholic fatty liver disease","volume":"130","author":"Smith","year":"2020","journal-title":"J Clin Investig"},{"issue":"2","key":"10.1016\/j.molmet.2025.102264_bib14","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1016\/j.jhep.2023.10.042","article-title":"Pharmacologic inhibition of lipogenesis for the treatment of NAFLD","volume":"80","author":"Esler","year":"2024","journal-title":"J Hepatol"},{"issue":"12","key":"10.1016\/j.molmet.2025.102264_bib15","doi-asserted-by":"crossref","DOI":"10.1016\/j.jlr.2024.100676","article-title":"Targeting acetyl-CoA carboxylases for the treatment of MASLD","volume":"65","author":"Mateo-Marin","year":"2024","journal-title":"J Lipid Res"},{"key":"10.1016\/j.molmet.2025.102264_bib16","article-title":"Acetyl-CoA carboxylases and diseases","volume":"12","author":"Wang","year":"2022","journal-title":"Front Oncol"},{"issue":"5","key":"10.1016\/j.molmet.2025.102264_bib17","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1128\/MCB.01122-06","article-title":"Hepatic de novo lipogenesis is present in liver-specific ACC1-deficient mice","volume":"27","author":"Harada","year":"2007","journal-title":"Mol Cell Biol"},{"issue":"2","key":"10.1016\/j.molmet.2025.102264_bib18","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.cmet.2022.01.001","article-title":"New avenues for NASH therapy by targeting ACC","volume":"34","author":"Bian","year":"2022","journal-title":"Cell Metab"},{"issue":"10","key":"10.1016\/j.molmet.2025.102264_bib19","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1038\/s42255-020-00272-9","article-title":"De novo lipogenesis is essential for platelet production in humans","volume":"2","author":"Kelly","year":"2020","journal-title":"Nat Metab"},{"issue":"2","key":"10.1016\/j.molmet.2025.102264_bib20","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1016\/j.cmet.2017.07.009","article-title":"Acetyl CoA carboxylase inhibition reduces hepatic steatosis but elevates plasma triglycerides in mice and humans: a bedside to bench investigation","volume":"26","author":"Kim","year":"2017","journal-title":"Cell Metab"},{"issue":"10","key":"10.1016\/j.molmet.2025.102264_bib21","doi-asserted-by":"crossref","first-page":"1836","DOI":"10.1038\/s41591-021-01489-1","article-title":"ACC inhibitor alone or co-administered with a DGAT2 inhibitor in patients with non-alcoholic fatty liver disease: two parallel, placebo-controlled, randomized phase 2a trials","volume":"27","author":"Calle","year":"2021","journal-title":"Nat Med"},{"issue":"5","key":"10.1016\/j.molmet.2025.102264_bib22","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1053\/j.gastro.2018.07.027","article-title":"GS-0976 reduces hepatic steatosis and fibrosis markers in patients with nonalcoholic fatty liver disease","volume":"155","author":"Loomba","year":"2018","journal-title":"Gastroenterology"},{"issue":"6","key":"10.1016\/j.molmet.2025.102264_bib23","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.1002\/hep.30097","article-title":"Acetyl-CoA carboxylase inhibition reverses NAFLD and hepatic insulin resistance but promotes hypertriglyceridemia in rodents","volume":"68","author":"Goedeke","year":"2018","journal-title":"Hepatology"},{"issue":"4","key":"10.1016\/j.molmet.2025.102264_bib24","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/j.molmet.2014.02.004","article-title":"Genetic inhibition of hepatic acetyl-CoA carboxylase activity increases liver fat and alters global protein acetylation","volume":"3","author":"Chow","year":"2014","journal-title":"Mol Metab"},{"issue":"1","key":"10.1016\/j.molmet.2025.102264_bib25","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.cmet.2009.11.008","article-title":"Acute or chronic upregulation of mitochondrial fatty acid oxidation has no net effect on whole-body energy expenditure or adiposity","volume":"11","author":"Hoehn","year":"2010","journal-title":"Cell Metab"},{"issue":"6","key":"10.1016\/j.molmet.2025.102264_bib26","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1002\/hep.20701","article-title":"Design and validation of a histological scoring system for nonalcoholic fatty liver disease","volume":"41","author":"Kleiner","year":"2005","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.molmet.2025.102264_bib27","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/S0021-9258(18)64849-5","article-title":"A simple method for the isolation and purification of total lipides from animal tissues","volume":"226","author":"Folch","year":"1957","journal-title":"J Biol Chem"},{"issue":"1","key":"10.1016\/j.molmet.2025.102264_bib28","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/s40170-024-00363-1","article-title":"Complete inhibition of liver acetyl-CoA carboxylase activity is required to exacerbate liver tumorigenesis in mice treated with diethylnitrosamine","volume":"12","author":"Shrestha","year":"2024","journal-title":"Cancer Metabol"},{"issue":"5","key":"10.1016\/j.molmet.2025.102264_bib29","doi-asserted-by":"crossref","first-page":"E1269","DOI":"10.1152\/ajpendo.90207.2008","article-title":"Validation of simple indexes to assess insulin sensitivity during pregnancy in Wistar and sprague-dawley rats","volume":"295","author":"Cacho","year":"2008","journal-title":"Am J Physiol Endocrinol Metab"},{"issue":"7","key":"10.1016\/j.molmet.2025.102264_bib30","doi-asserted-by":"crossref","first-page":"1790","DOI":"10.2337\/db07-1615","article-title":"Glucose metabolism in vivo in four commonly used inbred mouse strains","volume":"57","author":"Berglund","year":"2008","journal-title":"Diabetes"},{"issue":"7","key":"10.1016\/j.molmet.2025.102264_bib31","doi-asserted-by":"crossref","first-page":"G483","DOI":"10.1152\/ajpgi.00079.2013","article-title":"Diet-induced mouse model of fatty liver disease and nonalcoholic steatohepatitis reflecting clinical disease progression and methods of assessment","volume":"305","author":"Clapper","year":"2013","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"issue":"8","key":"10.1016\/j.molmet.2025.102264_bib32","doi-asserted-by":"crossref","first-page":"G762","DOI":"10.1152\/ajpgi.00476.2011","article-title":"Glucagon-like peptide-1 receptor agonism improves metabolic, biochemical, and histopathological indices of nonalcoholic steatohepatitis in mice","volume":"302","author":"Trevaskis","year":"2012","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"issue":"2","key":"10.1016\/j.molmet.2025.102264_bib33","doi-asserted-by":"crossref","first-page":"179","DOI":"10.3748\/wjg.v24.i2.179","article-title":"Metabolic and hepatic effects of liraglutide, obeticholic acid and elafibranor in diet-induced obese mouse models of biopsy-confirmed nonalcoholic steatohepatitis","volume":"24","author":"Tolbol","year":"2018","journal-title":"World J Gastroenterol"},{"issue":"5","key":"10.1016\/j.molmet.2025.102264_bib34","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1038\/s41575-023-00888-8","article-title":"Hepatic glucose metabolism in the steatotic liver","volume":"21","author":"Scoditti","year":"2024","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"12","key":"10.1016\/j.molmet.2025.102264_bib35","article-title":"Lipid metabolism in MASLD and MASH: from mechanism to the clinic","volume":"6","author":"Carli","year":"2024","journal-title":"JHEP Rep"},{"issue":"4","key":"10.1016\/j.molmet.2025.102264_bib36","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1038\/s41573-021-00367-2","article-title":"Lipogenesis inhibitors: therapeutic opportunities and challenges","volume":"21","author":"Batchuluun","year":"2022","journal-title":"Nat Rev Drug Discov"},{"issue":"6","key":"10.1016\/j.molmet.2025.102264_bib37","doi-asserted-by":"crossref","first-page":"2062","DOI":"10.1002\/hep.30206","article-title":"Trimming the fat: acetyl-coa carboxylase inhibition for the management of NAFLD","volume":"68","author":"Imai","year":"2018","journal-title":"Hepatology"},{"key":"10.1016\/j.molmet.2025.102264_bib38","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms14689","article-title":"Inhibition of hepatic lipogenesis enhances liver tumorigenesis by increasing antioxidant defence and promoting cell survival","volume":"8","author":"Nelson","year":"2017","journal-title":"Nat Commun"},{"issue":"22","key":"10.1016\/j.molmet.2025.102264_bib39","doi-asserted-by":"crossref","first-page":"8552","DOI":"10.1073\/pnas.0603115103","article-title":"Liver-specific deletion of acetyl-CoA carboxylase 1 reduces hepatic triglyceride accumulation without affecting glucose homeostasis","volume":"103","author":"Mao","year":"2006","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"5","key":"10.1016\/j.molmet.2025.102264_bib40","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1016\/j.cmet.2024.02.004","article-title":"Hepatic malonyl-CoA synthesis restrains gluconeogenesis by suppressing fat oxidation, pyruvate carboxylation, and amino acid availability","volume":"36","author":"Deja","year":"2024","journal-title":"Cell Metab"},{"issue":"1","key":"10.1016\/j.molmet.2025.102264_bib41","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1002\/hep4.1443","article-title":"Farnesoid X Receptor Agonism, Acetyl-Coenzyme A Carboxylase Inhibition, and Back Translation of Clinically Observed Endpoints of De Novo Lipogenesis in a Murine NASH Model","volume":"4","author":"Gapp","year":"2020","journal-title":"Hepatol Commun"},{"issue":"2","key":"10.1016\/j.molmet.2025.102264_bib42","doi-asserted-by":"crossref","DOI":"10.1530\/JOE-22-0270","article-title":"Fructose drives de novo lipogenesis affecting metabolic health","volume":"257","author":"Geidl-Flueck","year":"2023","journal-title":"J Endocrinol"},{"issue":"3","key":"10.1016\/j.molmet.2025.102264_bib43","article-title":"Bile acids mediate fructose-associated liver tumour growth in mice","volume":"1870","author":"Hargett","year":"2024","journal-title":"Biochim Biophys Acta Mol Basis Dis"},{"issue":"2","key":"10.1016\/j.molmet.2025.102264_bib44","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1039\/C1FO10111K","article-title":"Fructose containing sugars modulate mRNA of lipogenic genes ACC and FAS and protein levels of transcription factors ChREBP and SREBP1c with no effect on body weight or liver fat","volume":"3","author":"Janevski","year":"2012","journal-title":"Food Funct"},{"issue":"11","key":"10.1016\/j.molmet.2025.102264_bib45","doi-asserted-by":"crossref","first-page":"4372","DOI":"10.1172\/JCI81993","article-title":"ChREBP regulates fructose-induced glucose production independently of insulin signaling","volume":"126","author":"Kim","year":"2016","journal-title":"J Clin Investig"},{"issue":"1","key":"10.1016\/j.molmet.2025.102264_bib46","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.jhep.2021.02.027","article-title":"Fructose- and sucrose- but not glucose-sweetened beverages promote hepatic de novo lipogenesis: a randomized controlled trial","volume":"75","author":"Geidl-Flueck","year":"2021","journal-title":"J Hepatol"},{"issue":"15","key":"10.1016\/j.molmet.2025.102264_bib47","doi-asserted-by":"crossref","first-page":"12578","DOI":"10.1074\/jbc.M111.309559","article-title":"Acetyl-CoA carboxylase 2-\/- mutant mice are protected against fatty liver under high-fat, high-carbohydrate dietary and de novo lipogenic conditions","volume":"287","author":"Abu-Elheiga","year":"2012","journal-title":"J Biol Chem"},{"issue":"18","key":"10.1016\/j.molmet.2025.102264_bib48","doi-asserted-by":"crossref","first-page":"10207","DOI":"10.1073\/pnas.1733877100","article-title":"Acetyl-CoA carboxylase 2 mutant mice are protected against obesity and diabetes induced by high-fat\/high-carbohydrate diets","volume":"100","author":"Abu-Elheiga","year":"2003","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"42","key":"10.1016\/j.molmet.2025.102264_bib49","doi-asserted-by":"crossref","first-page":"16480","DOI":"10.1073\/pnas.0706794104","article-title":"Continuous fat oxidation in acetyl-CoA carboxylase 2 knockout mice increases total energy expenditure, reduces fat mass, and improves insulin sensitivity","volume":"104","author":"Choi","year":"2007","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"5513","key":"10.1016\/j.molmet.2025.102264_bib50","doi-asserted-by":"crossref","first-page":"2613","DOI":"10.1126\/science.1056843","article-title":"Continuous fatty acid oxidation and reduced fat storage in mice lacking acetyl-CoA carboxylase 2","volume":"291","author":"Abu-Elheiga","year":"2001","journal-title":"Science"},{"issue":"8","key":"10.1016\/j.molmet.2025.102264_bib51","doi-asserted-by":"crossref","first-page":"3007","DOI":"10.1210\/en.2018-00338","article-title":"ACC2 deletion enhances IMCL reduction along with Acetyl-CoA metabolism and improves insulin sensitivity in Male mice","volume":"159","author":"Takagi","year":"2018","journal-title":"Endocrinology"},{"issue":"3","key":"10.1016\/j.molmet.2025.102264_bib52","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1530\/JOE-15-0444","article-title":"Minimal impact of age and housing temperature on the metabolic phenotype of Acc2-\/- mice","volume":"228","author":"Brandon","year":"2016","journal-title":"J Endocrinol"},{"issue":"16","key":"10.1016\/j.molmet.2025.102264_bib53","doi-asserted-by":"crossref","first-page":"7598","DOI":"10.1073\/pnas.0913492107","article-title":"Gene knockout of Acc2 has little effect on body weight, fat mass, or food intake","volume":"107","author":"Olson","year":"2010","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"19","key":"10.1016\/j.molmet.2025.102264_bib54","doi-asserted-by":"crossref","DOI":"10.1074\/jbc.O112.356915","article-title":"Phenotypic discrepancies in acetyl-CoA carboxylase 2-deficient mice","volume":"287","author":"Hoehn","year":"2012","journal-title":"J Biol Chem"},{"issue":"3","key":"10.1016\/j.molmet.2025.102264_bib55","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1172\/JCI27300","article-title":"Reversal of diet-induced hepatic steatosis and hepatic insulin resistance by antisense oligonucleotide inhibitors of acetyl-CoA carboxylases 1 and 2","volume":"116","author":"Savage","year":"2006","journal-title":"J Clin Investig"},{"issue":"12","key":"10.1016\/j.molmet.2025.102264_bib56","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1038\/nm.3372","article-title":"Single phosphorylation sites in Acc1 and Acc2 regulate lipid homeostasis and the insulin-sensitizing effects of metformin","volume":"19","author":"Fullerton","year":"2013","journal-title":"Nat Med"},{"issue":"2","key":"10.1016\/j.molmet.2025.102264_bib57","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1002\/hep.31622","article-title":"Combination therapies including Cilofexor and firsocostat for bridging fibrosis and cirrhosis attributable to NASH","volume":"73","author":"Loomba","year":"2021","journal-title":"Hepatology"},{"issue":"2","key":"10.1016\/j.molmet.2025.102264_bib58","doi-asserted-by":"crossref","first-page":"E187","DOI":"10.1152\/ajpendo.00161.2022","article-title":"Investigating dual inhibition of ACC and CD36 for the treatment of nonalcoholic fatty liver disease in mice","volume":"324","author":"Devereux","year":"2023","journal-title":"Am J Physiol Endocrinol Metab"},{"issue":"3","key":"10.1016\/j.molmet.2025.102264_bib59","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1124\/jpet.121.000786","article-title":"Selective Acetyl-CoA carboxylase 1 inhibitor improves hepatic steatosis and hepatic fibrosis in a preclinical nonalcoholic steatohepatitis model","volume":"379","author":"Tamura","year":"2021","journal-title":"J Pharmacol Exp Ther"},{"issue":"4","key":"10.1016\/j.molmet.2025.102264_bib60","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1016\/j.jhep.2020.04.037","article-title":"Acetyl-CoA carboxylase inhibition disrupts metabolic reprogramming during hepatic stellate cell activation","volume":"73","author":"Bates","year":"2020","journal-title":"J Hepatol"},{"issue":"2","key":"10.1016\/j.molmet.2025.102264_bib61","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1080\/13543784.2020.1668374","article-title":"GS-0976 (Firsocostat): an investigational liver-directed acetyl-CoA carboxylase (ACC) inhibitor for the treatment of non-alcoholic steatohepatitis (NASH)","volume":"29","author":"Alkhouri","year":"2020","journal-title":"Expet Opin Invest Drugs"},{"issue":"Supplement_1","key":"10.1016\/j.molmet.2025.102264_bib62","doi-asserted-by":"crossref","DOI":"10.2337\/db23-849-P","article-title":"849-P: antidiabetic effects of TLC-3595, a selective ACC2 inhibitor, in ZDF rats","volume":"72","author":"Vijayakumar","year":"2023","journal-title":"Diabetes"},{"issue":"Supplement_1","key":"10.1016\/j.molmet.2025.102264_bib63","doi-asserted-by":"crossref","DOI":"10.2337\/db24-899-P","article-title":"899-P: combinations of the mitochondrial protonophore TLC-6740 and\/or the ACC2 inhibitor TLC-3595 provide additive glycemic benefits to semaglutide (SEMA) in db\/db mice","volume":"73","author":"Vijayakumar","year":"2024","journal-title":"Diabetes"},{"issue":"5","key":"10.1016\/j.molmet.2025.102264_bib64","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1002\/hep.27320","article-title":"Lysyl oxidase-like 2 is critical to tumor microenvironment and metastatic niche formation in hepatocellular carcinoma","volume":"60","author":"Wong","year":"2014","journal-title":"Hepatology"},{"issue":"14","key":"10.1016\/j.molmet.2025.102264_bib65","doi-asserted-by":"crossref","DOI":"10.3390\/ijms241411745","article-title":"Multiple roles of LOXL2 in the progression of hepatocellular carcinoma and its potential for therapeutic targeting","volume":"24","author":"Radic","year":"2023","journal-title":"Int J Mol Sci"}],"container-title":["Molecular Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2212877825001711?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2212877825001711?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T22:07:01Z","timestamp":1773180421000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2212877825001711"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":65,"alternative-id":["S2212877825001711"],"URL":"https:\/\/doi.org\/10.1016\/j.molmet.2025.102264","relation":{},"ISSN":["2212-8778"],"issn-type":[{"value":"2212-8778","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Isotype-selective roles of hepatic acetyl-CoA carboxylases in a mouse model of fatty liver disease","name":"articletitle","label":"Article Title"},{"value":"Molecular Metabolism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.molmet.2025.102264","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier GmbH.","name":"copyright","label":"Copyright"}],"article-number":"102264"}}